S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PGEN

Precigen (PGEN) Stock Price, News & Analysis

$1.45
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$1.42
$1.47
50-Day Range
$1.28
$1.75
52-Week Range
$0.84
$1.88
Volume
676,398 shs
Average Volume
1.10 million shs
Market Capitalization
$360.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Precigen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
589.7% Upside
$10.00 Price Target
Short Interest
Bearish
13.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.38mentions of Precigen in the last 14 days
Based on 18 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.32) to ($0.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

186th out of 938 stocks

Pharmaceutical Preparations Industry

78th out of 432 stocks

PGEN stock logo

About Precigen Stock (NASDAQ:PGEN)

Precigen, Inc. operates as a discovery and clinical stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company, through its technologies, enables to find solutions for biotherapeutics. The company operates as an engine progressing a preclinical and clinical pipeline of therapies toward clinical proof-of-concept and commercialization. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

PGEN Stock Price History

PGEN Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Precigen (NASDAQ:PGEN) Upgraded to Sell by StockNews.com
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Precigen's (PGEN) Buy Rating Reiterated at HC Wainwright
Recap: Precigen Q4 Earnings
Preview: Precigen's Earnings
See More Headlines
Receive PGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PGEN
Fax
N/A
Employees
209
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$14.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+589.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-95,900,000.00
Net Margins
-1,540.63%
Pretax Margin
-1,547.98%

Debt

Sales & Book Value

Annual Sales
$6.22 million
Book Value
$0.48 per share

Miscellaneous

Free Float
145,120,000
Market Cap
$360.93 million
Optionable
Optionable
Beta
1.73
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

PGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Precigen stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PGEN, but not buy additional shares or sell existing shares.
View PGEN analyst ratings
or view top-rated stocks.

What is Precigen's stock price target for 2024?

3 brokerages have issued 12-month price objectives for Precigen's shares. Their PGEN share price targets range from $6.00 to $14.00. On average, they anticipate the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 589.7% from the stock's current price.
View analysts price targets for PGEN
or view top-rated stocks among Wall Street analysts.

How have PGEN shares performed in 2024?

Precigen's stock was trading at $1.34 at the beginning of 2024. Since then, PGEN stock has increased by 8.2% and is now trading at $1.45.
View the best growth stocks for 2024 here
.

When is Precigen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PGEN earnings forecast
.

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) announced its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.01. The biotechnology company earned $21.56 million during the quarter, compared to analyst estimates of $24.47 million. Precigen had a negative net margin of 1,540.63% and a negative trailing twelve-month return on equity of 55.47%.

What ETF holds Precigen's stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 87,692 shares of PGEN stock, representing 0.90% of its portfolio.

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).

Who are Precigen's major shareholders?

Precigen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Patient Capital Management LLC (6.42%), Vanguard Group Inc. (2.71%), Vanguard Group Inc. (2.71%), Iridian Asset Management LLC CT (0.81%), Northern Trust Corp (0.43%) and Opaleye Management Inc. (0.41%). Insiders that own company stock include David M Obstler, Dean J Mitchell, Donald P Lehr, Harry Jr Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Jennifer I Ansberry, John N Digiacomo, Randal J Kirk, Rutul R Shah, Steven Frank and Trading SA Ares.
View institutional ownership trends
.

How do I buy shares of Precigen?

Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PGEN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners